Literature DB >> 16103155

Alpha/beta interferon differentially modulates the clearance of cytoplasmic encapsidated replication intermediates and nuclear covalently closed circular hepatitis B virus (HBV) DNA from the livers of hepatocyte nuclear factor 1alpha-null HBV transgenic mice.

Aimee L Anderson1, Krista E Banks, Marco Pontoglio, Moshe Yaniv, Alan McLachlan.   

Abstract

Treatment with alpha interferon is a standard therapy for patients with chronic hepatitis B virus (HBV) infections. This treatment can reduce virus load and ameliorate disease symptoms. However, in the majority of cases, alpha interferon therapy fails to resolve the chronic HBV infection. The reason alpha interferon therapy is inefficient at resolving chronic HBV infections is assumed to be because it fails to eliminate covalently closed circular (CCC) HBV DNA from the nuclei of infected hepatocytes. In an attempt to address this issue, the stability of HBV CCC DNA in response to alpha/beta interferon induction was examined in HNF1alpha-null HBV transgenic mice. Alpha/beta interferon induction by polyinosinic-polycytidylic acid [poly(I-C)] treatment efficiently eliminated encapsidated cytoplasmic HBV replication intermediates while only modestly reducing nuclear HBV CCC DNA. These observations indicate that nuclear HBV CCC DNA is more stable than cytoplasmic replication intermediates in response to alpha/beta interferon induction. Consequently it appears that for therapies to resolve chronic HBV infection efficiently, they will have to target the elimination of the most stable HBV replication intermediate, nuclear HBV CCC DNA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103155      PMCID: PMC1193586          DOI: 10.1128/JVI.79.17.11045-11052.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Low dynamic state of viral competition in a chronic avian hepadnavirus infection.

Authors:  Y Y Zhang; J Summers
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism.

Authors:  D Q Shih; M Bussen; E Sehayek; M Ananthanarayanan; B L Shneider; F J Suchy; S Shefer; J S Bollileni; F J Gonzalez; J L Breslow; M Stoffel
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

3.  Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice.

Authors:  A K Raney; C M Eggers; E F Kline; L G Guidotti; M Pontoglio; M Yaniv; A McLachlan
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines.

Authors:  H McClary; R Koch; F V Chisari; L G Guidotti
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Regulation of the liver fatty acid-binding protein gene by hepatocyte nuclear factor 1alpha (HNF1alpha). Alterations in fatty acid homeostasis in HNF1alpha-deficient mice.

Authors:  T E Akiyama; J M Ward; F J Gonzalez
Journal:  J Biol Chem       Date:  2000-09-01       Impact factor: 5.157

6.  Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.

Authors:  Y Zhu; T Yamamoto; J Cullen; J Saputelli; C E Aldrich; D S Miller; S Litwin; P A Furman; A R Jilbert; W S Mason
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

Authors:  C L Lai; C K Ching; A K Tung; E Li; J Young; A Hill; B C Wong; J Dent; P C Wu
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

8.  Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice.

Authors:  S F Wieland; L G Guidotti; F V Chisari
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

9.  Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA.

Authors:  M Dandri; M R Burda; H Will; J Petersen
Journal:  Hepatology       Date:  2000-07       Impact factor: 17.425

10.  Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA, and protein expression.

Authors:  C Luscombe; J Pedersen; E Uren; S Locarnini
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

View more
  12 in total

1.  Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein.

Authors:  Weifan Gao; Jianming Hu
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

2.  Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells.

Authors:  Richeng Mao; Jiming Zhang; Dong Jiang; Dawei Cai; Jessica M Levy; Andrea Cuconati; Timothy M Block; Ju-Tao Guo; Haitao Guo
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

3.  Limited effects of bile acids and small heterodimer partner on hepatitis B virus biosynthesis in vivo.

Authors:  Vanessa C Reese; David D Moore; Alan McLachlan
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

4.  Application of hepatitis B virus replication mouse model.

Authors:  Zhan Gao; Feng-Jun Liu; Li Liu; Tao-You Zhou; Jun Lei; Lu Xu; Cong Liu; Jie Dai; En-Qiang Chen; Hong Tang
Journal:  World J Gastroenterol       Date:  2010-04-28       Impact factor: 5.742

5.  Establishment and primary application of a mouse model with hepatitis B virus replication.

Authors:  Feng-Jun Liu; Li Liu; Fang He; Su Wang; Tao-You Zhou; Cong Liu; Lin-Yu Deng; Hong Tang
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

6.  Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.

Authors:  Raymond F Schinazi; Leda Bassit; Marcia M Clayton; Bill Sun; James J Kohler; Aleksandr Obikhod; Alla Arzumanyan; Mark A Feitelson
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

7.  Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B.

Authors:  Simon P Fletcher; Daniel J Chin; Lore Gruenbaum; Hans Bitter; Erik Rasmussen; Palanikumar Ravindran; David C Swinney; Fabian Birzele; Roland Schmucki; Stefan H Lorenz; Erhard Kopetzki; Jade Carter; Miriam Triyatni; Linta M Thampi; Junming Yang; Dalal AlDeghaither; Marta G Murreddu; Marta G Murredu; Paul Cote; Stephan Menne
Journal:  PLoS Pathog       Date:  2015-09-09       Impact factor: 6.823

8.  Hepatic deficiency of the pioneer transcription factor FoxA restricts hepatitis B virus biosynthesis by the developmental regulation of viral DNA methylation.

Authors:  Vanessa C McFadden; Rasha E Shalaby; Saira Iram; Claudia E Oropeza; Jennifer A Landolfi; Alexander V Lyubimov; Mark Maienschein-Cline; Stefan J Green; Klaus H Kaestner; Alan McLachlan
Journal:  PLoS Pathog       Date:  2017-02-24       Impact factor: 6.823

9.  β-Catenin Signaling Regulates the In Vivo Distribution of Hepatitis B Virus Biosynthesis across the Liver Lobule.

Authors:  Grant Tarnow; Alan McLachlan
Journal:  J Virol       Date:  2021-07-28       Impact factor: 5.103

10.  Developmental regulation of hepatitis B virus biosynthesis by hepatocyte nuclear factor 4alpha.

Authors:  Lie Li; Claudia E Oropeza; Bruno Sainz; Susan L Uprichard; Frank J Gonzalez; Alan McLachlan
Journal:  PLoS One       Date:  2009-05-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.